Research Analysts Offer Predictions for NTLA FY2027 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Equities research analysts at Zacks Research issued their FY2027 EPS estimates for shares of Intellia Therapeutics in a report released on Thursday, March 20th. Zacks Research analyst R. Department forecasts that the company will post earnings of ($4.87) per share for the year. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share.

NTLA has been the topic of several other research reports. Wells Fargo & Company reduced their price target on shares of Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Morgan Stanley lowered shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $56.00 to $11.00 in a research report on Monday, January 27th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $13.00 price target (down previously from $45.00) on shares of Intellia Therapeutics in a research report on Friday, February 28th. Chardan Capital cut their target price on Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating on the stock in a research report on Friday, February 28th. Finally, The Goldman Sachs Group reissued a “sell” rating and issued a $9.00 target price on shares of Intellia Therapeutics in a research report on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $37.56.

Intellia Therapeutics Stock Performance

NTLA stock opened at $9.00 on Monday. The firm has a market cap of $931.65 million, a PE ratio of -1.65 and a beta of 1.97. The firm’s 50 day moving average price is $10.09 and its 200-day moving average price is $14.13. Intellia Therapeutics has a one year low of $8.30 and a one year high of $28.23.

Hedge Funds Weigh In On Intellia Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Capstone Investment Advisors LLC grew its stake in shares of Intellia Therapeutics by 1.4% during the third quarter. Capstone Investment Advisors LLC now owns 61,129 shares of the company’s stock worth $1,256,000 after purchasing an additional 831 shares in the last quarter. Ensign Peak Advisors Inc grew its stake in shares of Intellia Therapeutics by 2.9% during the fourth quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company’s stock worth $457,000 after purchasing an additional 1,100 shares in the last quarter. Franklin Resources Inc. grew its stake in shares of Intellia Therapeutics by 10.3% during the third quarter. Franklin Resources Inc. now owns 16,405 shares of the company’s stock worth $320,000 after purchasing an additional 1,538 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Intellia Therapeutics by 14.0% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 12,863 shares of the company’s stock worth $157,000 after purchasing an additional 1,582 shares in the last quarter. Finally, Arizona State Retirement System grew its stake in shares of Intellia Therapeutics by 6.1% during the fourth quarter. Arizona State Retirement System now owns 28,006 shares of the company’s stock worth $327,000 after purchasing an additional 1,615 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Insiders Place Their Bets

In related news, CEO John M. Leonard sold 26,807 shares of the business’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the transaction, the chief executive officer now owns 941,115 shares in the company, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold a total of 29,000 shares of company stock worth $352,551 over the last 90 days. Corporate insiders own 3.20% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.